| CAS NO. |
Products Name |
| 1628830-21-6 |
EZM2302 |
more... |
| EZM 2302 is an inhibitor of coactivator-associated arginine methyltransferase 1 (CARM1) with an IC50 of 6 nM. |
|
|
|
| 1310726-60-3 |
Upadacitinib |
more... |
| Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) is used in development for the treatment of several autoimmune disorders |
|
| 1628208-23-0 |
CPI-455 |
more... |
| CPI-455 is a specific, pan-KDM5 inhibitor with an IC50 of 10 nM for KDM5A. CPI-455 mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents |
|
| 440662-09-9 |
CeMMEC1 |
more... |
| CeMMEC1 is an inhibitor of BRD4, and also has high affinity for TAF1, with an IC50 of 0.9 μM for TAF1, and a Kd of 1.8 μM for TAF1 |
|
|
|
| 1627929-55-8 |
PLX51107 |
more... |
| PLX51107 is a potent and selective BET inhibitor, with Kds of 1.6, 2.1, 1.7, and 5 nM for BD1 and 5.9, 6.2, 6.1, and 120 nM for BD2 of BRD2, BRD3, BRD4, and BRDT, respectively; PLX51107 also interacts with the bromodomains of CBP and EP300 (Kd, in the 100 nM range). |
|
| 1628317-18-9 |
MI463 |
more... |
| MI-463 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction. |
|
| 1857417-13-0 |
MI503 |
more... |
| MI-503 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction. |
|
| 1821908-48-8 |
SGC-2085 |
more... |
| SGC2085 is a potent and selective coactivator associated arginine methyltransferase 1 (CARM1) inhibitor with an IC50 of 50 nM. |
|
| 1261289-04-6 |
O-304 |
more... |
| O-304 is a first-in-class, orally available pan-AMPK activator, which increases AMPK activity by suppressing the dephosphorylation of pAMPK. O-304 exhibits a great potential as a drug to treat type 2 diabetes (T2D) and associated cardiovascular complications |
|
|
|
All Products
